Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.

Seminars in Oncology
A Jo Chien, Mark M Moasser

Abstract

Taxanes and anthracyclines are two of the most potent and broadly effective classes of chemotherapeutic agents. However, resistance to these agents is common and significantly limits their potential. As such, there is a great need to understand the mechanisms underlying de novo and acquired resistance to these agents. Beyond the resistance barrier lies even greater potential to significantly alter the natural course of human cancer. This review discusses what we currently understand about the mechanisms of resistance to taxanes and anthracyclines. Preclinical models suggest a role for ATP-binding cassette transporters, tubulin isoforms, microtubule-associated proteins, tubulin gene mutations, and mitotic checkpoint signaling proteins in resistance to taxanes. Preclinical models also suggest that drug transport proteins, antioxidant defenses, apoptotic signaling, and topoisomerase modulation may mediate anthracycline resistance. Many of these hypotheses remain untested in appropriately designed clinical studies, but limited clinical evidence will be reviewed. Epothilones represent a novel class of non-taxane microtubule stabilizing agents with distinct drug-resistance profiles. Potential mechanisms behind these differences and t...Continue Reading

References

Feb 22, 1979·Nature·P B SchiffS B Horwitz
Dec 1, 1990·Breast Cancer Research and Treatment·J BustamanteA Boveris
Jun 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·K F Sullivan, D W Cleveland
Nov 1, 1981·The Journal of Cell Biology·J Parness, S B Horwitz
Sep 1, 1982·The Journal of Cell Biology·J J ManfrediS B Horwitz
May 4, 1995·International Journal of Cancer. Journal International Du Cancer·F VikhanskayaM Broggini
May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·S HaldarC M Croce
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·D PandaL Wilson
Oct 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M A JordanL Wilson
Apr 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·V T Marchesi, N Ngo
Sep 18, 1996·Journal of the National Cancer Institute·C G MilrossL Milas
Oct 11, 1996·Biochemical Pharmacology·D LautierS P Cole
Mar 1, 1996·Trends in Biochemical Sciences·M D Jacobson
Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E MoranM Clynes
Jun 1, 1997·Seminars in Cancer Biology·A H Schinkel
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·T C ChouS J Danishefsky
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A M CodegoniM Broggini
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·L A DoyleD D Ross
Aug 14, 1999·The Journal of Biological Chemistry·M L Gonzalez-GarayF Cabral
Oct 8, 1999·Journal of the National Cancer Institute·W S Dalton, R J Scheper
Oct 8, 1999·Journal of the National Cancer Institute·M KitazonoS Akiyama

❮ Previous
Next ❯

Citations

Aug 3, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Marie EhrlichováIvan Gut
Nov 25, 2011·Breast Cancer Research and Treatment·Javier Cortes, Maria Vidal
Mar 29, 2013·Breast Cancer Research and Treatment·John M S BartlettPeter J Barrett-Lee
Dec 17, 2009·Investigational New Drugs·Jana VobořilováJan Kovář
Mar 31, 2010·Magyar onkologia·Nagykálnai TamásMészáros Edina
Oct 17, 2008·Expert Opinion on Investigational Drugs·Ulrich KlarMarius Giurescu
Mar 13, 2009·Expert Opinion on Emerging Drugs·Omer Dizdar, Kadri Altundag
Oct 19, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Alex Chang
Feb 3, 2009·Journal of Theoretical Biology·C J EvansS W Smye
Apr 23, 2010·The Breast Journal·Amelia Zelnak
Jun 10, 2010·Clinical Journal of Oncology Nursing·Jane Hurtig
Jun 13, 2015·BMC Complementary and Alternative Medicine·Ye HeXuezhen Hu
Mar 22, 2013·Carcinogenesis·Mattaka KhongkowEric W-F Lam
Jul 31, 2019·International Journal of Molecular Sciences·Yi Xiao, David Meierhofer
Dec 10, 2013·The Oncologist·Nicholas J Short, Jean M Connors
Feb 14, 2020·Journal of Cellular Physiology·Janusz Matuszyk, Dagmara Klopotowska
Apr 22, 2020·ChemMedChem·Maristela B Martins-Teixeira, Ivone Carvalho
Dec 14, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ying WuXichun Hu
Dec 13, 2017·International Journal of Molecular Sciences·Simona SeriniGabriella Calviello
Jul 9, 2016·Anti-cancer Drugs·Salome ArobelidzeHamed Daw
Apr 17, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia VrignaudMarie-Christine Bissery

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Tito Fojo, M Menefee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jennifer A LowSandra M Swain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Eva ThomasHenri H Roché
© 2022 Meta ULC. All rights reserved